Neil Gallagher - 05 Feb 2025 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Reporting relationship: President, Head of R&D
Issuer ticker: SNDX
Reported as of: 05 Feb 2025
Net transaction value: +$1,618,825
SEC form: 4
Accepted by SEC: 07 Feb 2025, 16:45:49 UTC
Prior SEC filing: 12 Dec 2024
Next SEC filing: 12 Feb 2025
Source filing: View source filing
Reporting owner signature: s/ Michael A. Metzger, as Attorney-in-Fact

Key filing fact

Neil Gallagher filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 07 Feb 2025.

Key facts

This page summarizes Neil Gallagher's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Feb 2025, 16:45.

Change

Previous filing in this sequence was filed on 12 Dec 2024.
Current net transaction value: +$1,618,825.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNDX transaction

Common Stock

Award

Transaction value: $0
Shares: +18,500
Change %: +39%
Price: $0.000000
Shares after: 66,313
Date: 05 Feb 2025
Ownership: Direct
Footnotes: F1

SNDX transaction

Common Stock

Award

Transaction value: $0
Shares: +23,400
Change %: +35%
Price: $0.000000
Shares after: 89,713
Date: 05 Feb 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNDX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $1,618,825
Shares: +110,500
Change %
Price: $14.65
Shares after: 110,500
Date: 05 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 110,500
Exercise price: $14.65
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested.

Footnote F2

Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company.

Footnote F3

1/48th of the shares subject to the option shall vest monthly over a four-year period.